Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tuberculosis.
Clinical trial NCT03255278 · COMPLETED
Trial details
- NCT number
- NCT03255278
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-15
- Primary completion
- 2017-12-13
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.